Related references
Note: Only part of the references are listed.A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density
Robert R. Recker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
The global burden attributable to low bone mineral density
L. Sanchez-Riera et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Progressive Increases in Bone Mass and Bone Strength in an Ovariectomized Rat Model of Osteoporosis After 26 Weeks of Treatment With a Sclerostin Antibody
Xiaodong Li et al.
ENDOCRINOLOGY (2014)
Single-and Multiple-Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women
Juliet McColm et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
The Impact of Nonhip Nonvertebral Fractures in Elderly Women and Men
Dana Bliuc et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Clinician's Guide to Prevention and Treatment of Osteoporosis
F. Cosman et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?
R. Sapir-Koren et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases
E. Michael Lewiecki
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2014)
Osteoporosis and fragility fractures
Paul Gerdhem
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2013)
Public Health Impact of Osteoporosis
Jane A. Cauley
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2013)
Recent Progress in Osteocyte Research
Paola Divieti Pajevic
ENDOCRINOLOGY AND METABOLISM (2013)
Theoretical Analysis of Interplay of Therapeutic Protein Drug and Circulating Soluble Target: Temporal Profiles of 'Free' and 'Total' Drug and Target
Cuyue Tang et al.
PHARMACEUTICAL RESEARCH (2011)
Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets
Jasmine P. Davda et al.
MABS (2010)
Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations
Raymond G. Slavin et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
A novel method for quantitative measurement of a biomarker in the presence of a therapeutic monoclonal antibody directed against the biomarker
R. Aleks Davis et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
Predictive value of BMD for hip and other fractures
O Johnell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation
RL Bezooijen et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Bone's mechanostat: A 2003 update
HM Frost
ANATOMICAL RECORD PART A-DISCOVERIES IN MOLECULAR CELLULAR AND EVOLUTIONARY BIOLOGY (2003)
BMD at multiple sites and risk of fracture of multiple types: Long-term results from the study of osteoporotic fractures
KL Stone et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (Serum CTx): Effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting
P Qvist et al.
BONE (2002)
Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis
CM Klotzbuecher et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)